A kind of preparation method of Zaleplon

A technology of zaleplon and synthetic route, applied in organic chemistry, etc., can solve the problem of high yield, achieve the effect of short route, reduce synthesis cost, and increase yield

Active Publication Date: 2022-03-04
XINXIANG MEDICAL UNIV +1
View PDF4 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

[0011] In 2020, Chinese patent CN107973800 reported the use of N-ethyl-N-(3-(pyrazolo[1,5-a]pyrimidin-7-yl)phenyl)acetamide and trimethylsilylacetonitrile in the presence of acridine Carry out light reaction in the reaction solvent of salt catalyst, directly realize cyanation reaction and prepare zaleplon, although this preparation route is short, and yield is high, but the raw material N-ethyl-N-(3-(pyrazolo [1,5-a]pyrimidin-7-yl)phenyl)acetamide requires multi-step pre-preparation

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • A kind of preparation method of Zaleplon
  • A kind of preparation method of Zaleplon
  • A kind of preparation method of Zaleplon

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0025] Preparation of compound 3

[0026]

[0027] Add m-nitrobenzaldehyde 1 (75.5mg, 0.5mmol), 3-amino-4-cyanopyrazole 2 (54mg, 0.5mmol), triethylamine (101mg, 1mmol), ammonium iodide in a 35mL sealed tube (72.5mg, 0.5mmol), di-tert-butyl peroxide (219mg, 1.5mmol) and toluene (2mL), then placed in an oil bath at 130°C and stirred for 10h. Add 50mL of water to quench the reaction, extract with ethyl acetate (50mL×3), and then the organic phase is treated with 10% Na 2 S 2 o 3 The solution was washed successively with saturated brine, and dried over anhydrous sodium sulfate. It was filtered, spin-dried, and separated by silica gel column (petroleum ether / ethyl acetate=3 / 1, v / v) to obtain compound 3 (114 mg, 86%) as a yellow solid product. The characterization data of this compound are as follows: 1 H NMR (400MHz, DMSO-d 6 ): δ (ppm) 8.97 (d, J = 1.6Hz, 1H), 8.95 (d, J = 4.8Hz, 1H), 8.88 (s, 1H), 8.48 (dd, J = 8.0, 2.0Hz, 2H) ,7.92(t,J=8.0Hz,1H),7.72(d,J=4.4Hz,1H); 13...

Embodiment 2

[0029] Preparation of Compound 4

[0030]

[0031] Iron powder (184.8 mg, 3.3 mmol) and glacial acetic acid (20 mL) were put into a three-necked flask, stirred and heated to reflux, acidified for 10 min, and a solution of compound 3 (265 mg, 1 mmol) in glacial acetic acid (25 mL) was added dropwise. After the dropwise addition, continue to reflux for 4h. The reaction was quenched by adding 50 mL of water, extracted with ethyl acetate (50 mL×3), and then the organic phase was washed with saturated brine and dried over anhydrous sodium sulfate. Filtered, spin-dried, and dried to give compound 4 (230 mg, 83%) as a white solid. The characterization data of this compound are as follows: 1 HNMR (400MHz, DMSO-d 6 ):δ(ppm)10.25(s,1H),8.89(d,J=4.4Hz,1H),8.86(s,1H),8.32(t,J=1.8Hz,1H),7.85–7.81(m, 1H), 7.70–7.67(m, 1H), 7.54(t, J=8.0Hz, 1H), 7.50(d, J=4.8Hz, 1H), 2.08(s, 3H); 13 C NMR (100MHz, DMSO-d 6 ):δ(ppm)168.7,153.8,151.1,147.5,147.3,139.4,129.9,129.1,124.3,122.0,119.9,113...

Embodiment 3

[0033] Preparation of compound 5

[0034]

[0035]Sodium hydride (58mg, 2.4mmol) and anhydrous DMF (2mL) were put into a three-necked flask filled with nitrogen, stirred in an ice-water bath, a DMF (6mL) solution of compound 4 (110.8mg, 0.4mmol) was added dropwise, and After the addition was completed, reacted for 5 minutes, added bromoethane (436 mg, 4 mmol) dropwise, and continued to stir in an ice-water bath for 30 minutes. It was extracted with ethyl acetate (50 mL×3), and the organic phase was washed with saturated brine and dried over anhydrous sodium sulfate. Filtered, spin-dried, and dried to give compound 5 (103.7 mg, 85%) as a white solid. The characterization data of this compound are as follows: 1 H NMR (400MHz, DMSO-d 6 ): δ (ppm) 8.92 (d, J = 4.4Hz, 1H), 8.87 (d, J = 0.4Hz, 1H), 8.09 (d, J = 7.6Hz, 1H), 8.04 (s, 1H), 7.71 (t, J=7.8Hz, 1H), 7.67(d, J=4.4Hz, 1H), 7.61(d, J=7.2Hz, 1H), 3.70(q, J=6.8Hz, 2H), 1.81(s ,3H),1.03(t,J=6.8Hz,3H); 13 C NMR (100MHz, ...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

No PUM Login to view more

Abstract

The invention discloses a preparation method of zaleplon and belongs to the technical field of medicinal chemistry. The present invention adopts simple and cheap m-nitrobenzaldehyde and triethylamine as raw materials, and constructs the core skeleton of zaleplon with high efficiency and high selectivity through a one-pot series reaction without transition metal catalysis, thereby avoiding the generation of isomers, The generation of by-products is reduced, the yield of the target product is improved, and the synthesis cost is reduced; afterward, zaleplon is prepared through simple nitro reduction modification. The whole route is short, the reaction conditions are mild, the operation is simple and convenient, and it is suitable for industrial production.

Description

technical field [0001] The invention belongs to the technical field of medicinal chemistry, and in particular relates to a preparation method of zaleplon. Background technique [0002] Zaleplon (Zaleplon), the chemical name is N-[3-(3-cyanopyrazolo[1,5-a]pyrimidin-7-yl)phenyl]-N-ethylacetamide, which is the United States A novel pyrazolopyrimidine sedative-hypnotics developed by Wyeth-Ayerst. In March 1999, the European Union approved zaleplon for the treatment of insomnia, and in August 1999, the US FDA approved zaleplon for adult insomnia. First launched in Denmark and Sweden in July 1999. Zaleplon, as a third-generation non-benzodiazepine sedative-hypnotics that has been used in clinical practice, is a complete agonist of benzodiazepine ω1 receptors, with short half-life, good curative effect, few side effects, and no spirit It is mainly used for the short-term treatment of adult insomnia. It can make insomnia patients fall asleep quickly, shorten the time to fall asle...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
Patent Type & Authority Patents(China)
IPC IPC(8): C07D487/04
CPCC07D487/04
Inventor 高庆贺韩新亚徐永涛段迎超吕洁丽房立真张妍严菊芬李莹莹
Owner XINXIANG MEDICAL UNIV
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap